Target intelligence / Profile preview

Alpha-7 neuronal nicotinic acetylcholine receptor (α7 nAChR) (α7 nAChR)

Target
α7 nAChR
Molecular classification
Ion channel, Ligand-gated ion channel, Nicotinic acetylcholine receptor, Cys-loop receptor family
01

Overview

The alpha-7 neuronal nicotinic acetylcholine receptor (α7 nAChR) is a homopentameric ligand-gated ion channel predominantly expressed in the brain, specifically within the hippocampus and cerebral cortex [1]. It is distinguished by its high permeability to calcium ions and rapid desensitization, which allows it to effectively modulate the release of other neurotransmitters such as glutamate and GABA [4]. This receptor plays a vital role in cognitive processes, including attention, memory, and sensory gating [3]. In clinical pathology, α7 nAChR dysfunction is strongly associated with the cognitive deficits observed in schizophrenia and Alzheimer's disease [3]. Varenicline, while primarily recognized as an α4β2 partial agonist for smoking cessation, also acts as a full agonist at the α7 receptor, contributing to its potential for cognitive enhancement [2]. Therapeutic targeting of this receptor aims to restore cholinergic signaling and provide neuroprotective effects in various neurodegenerative and psychiatric conditions [4].

Other names
CHRNA7Cholinergic receptor nicotinic alpha 7 subunitAlpha-7 nicotinic receptorNeuronal acetylcholine receptor subunit alpha-7NACHRA7
02

Mechanism of action

Full agonism (e.g., varenicline), partial agonism, and positive allosteric modulation [2, 4]

03

Biological functions

Fast excitatory synaptic transmission [1]Presynaptic modulation of neurotransmitter release (glutamate, GABA, dopamine) [4]High-permeability calcium signaling [4]Regulation of the cholinergic anti-inflammatory pathway [3]Synaptic plasticity and cognitive processing [3]
04

Disease associations

Schizophrenia [3]Alzheimer's disease [3]Cognitive impairment [3]Nicotine dependence [2]Systemic inflammation [3]
05

Safety considerations

Neuropsychiatric symptoms (agitation, hallucinations, suicidal ideation) [2]Gastrointestinal distress (nausea) [2]Sleep disturbances (insomnia, abnormal dreams) [2]Potential for seizures [2]
06

Interacting drugs

Varenicline

6 more in the full profile.

07

Biomarkers

P50 auditory evoked potential suppression [3]MATRICS Consensus Cognitive Battery (MCCB) scores [3][18F]ASEM PET imaging ligand binding [4]

Beyond the preview

Go deeper on Alpha-7 neuronal nicotinic acetylcholine receptor (α7 nAChR) (α7 nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-7 neuronal nicotinic acetylcholine receptor (α7 nAChR) (α7 nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call